Recursion (NASDAQ: RXRX) CFO has 25,018 shares withheld for taxes
Recursion (NASDAQ: RXRX) CFO Ben R. Taylor had 25,018 shares of Class A Common Stock withheld on August 17, 2026, to cover tax withholding obligations related to the net settlement of restricted stock units. The shares were valued at $3.16 each for this transaction. Following this event, Taylor directly holds 1,076,858 shares of Class A Common Stock.
Recursion (NASDAQ: RXRX) CEO's 80K shares withheld for RSU taxes
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) CEO Najat Khan had 80,498 shares of Class A Common Stock withheld on August 17, 2026, to cover tax obligations related to the net settlement of restricted stock units (RSUs). These shares were not sold in an open-market transaction, and after the withholding, Khan directly holds 2,095,298 shares. The value used for tax withholding was $3.16 per share.
Recursion (NASDAQ: RXRX) CSO sees 26K shares withheld for taxes
Recursion Pharmaceuticals (NASDAQ: RXRX) Chief Scientific Officer David Hallett had 26,657 shares of Class A common stock withheld on August 17, 2026, to satisfy tax obligations related to the net settlement of restricted stock units. This action was solely for tax purposes and not a market sale, reducing his direct holdings to 1,043,837 shares. The price per share for the tax withholding was $3.16.
Recursion Pharmaceuticals (RXRX) Stock Dropped, So What Is Behind The Move?
Recursion Pharmaceuticals (RXRX) recently reported its Q2 and H1 2026 results, showing lower sales but a narrower net loss, which impacted short-term stock sentiment. The company's stock experienced a 4.53% drop over one day, though some analysts see potential for future growth based on its AI healthcare focus and leadership changes. While one narrative suggests the stock is overvalued at $3.16 compared to a fair value of $1.97, a discounted cash flow model by Simply Wall St indicates it might be trading below an estimated future cash flow value of $9.80.
Recursion Pharmaceuticals (RXRX) Is Up 7.3% After Mixed Q2 Results With Narrower Net Loss
Recursion Pharmaceuticals reported mixed Q2 2026 results with a sharp revenue decline but a narrower net loss, indicating improved cost controls. The company's investment narrative remains tied to its AI-enabled drug discovery platform, requiring continuous R&D spending, external funding, and milestone payments. Despite reduced losses, future growth hinges on clinical progress and successful capital access, with analyst forecasts showing a wide range of potential outcomes.
Recursion Pharmaceuticals (RXRX) Stock Sinks As Cash Burn Dominates AI Drug Story
Recursion Pharmaceuticals (RXRX) saw its stock decline by 4% after reporting Q2 2026 revenue of US$7.67 million against a net loss of US$131.01 million, highlighting significant cash burn. Despite the financial losses, the company showed progress in its AI-driven drug discovery with clinical milestones and partnership validations. The market remains divided between the potential of its AI platform and concerns over its high cash burn and lack of immediate commercial products.
Recursion Pharmaceuticals (RXRX) director sells 30,000 shares in 10b5-1 plan
Recursion Pharmaceuticals (RXRX) director Blake Borgeson sold 30,000 shares of Class A Common Stock at $3.25 per share on August 4, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 31, 2025. Following the sale, Borgeson directly holds 6,188,287 shares of the company.
Recursion Pharmaceuticals (RXRX) Stock Looks Weak On Returns While Trading Above Fair Value
Recursion Pharmaceuticals (RXRX) stock has seen a significant decline over the past five years and is currently trading above its fair value based on various valuation checks. The company's P/S ratio of 30.7x is well above the biotech industry average, indicating it is expensive relative to its revenue. Despite a collaboration with Genentech, the stock's valuation remains a concern, with community opinions divided on its future prospects.
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
Recursion (Nasdaq: RXRX) announced its second-quarter 2026 financial results, highlighted by Genentech advancing the first neuroscience target from their collaboration into an early discovery program. This milestone validates Recursion's AI-native platform for identifying novel biological targets. The company also provided updates on its pipeline, including progress for REC-4881 in Familial Adenomatous Polyposis and the upcoming Phase 1/2 trial for REC-7735, and reduced its 2026 cash operating expense guidance.
Vanguard Capital Management (RXRX) discloses 26.7M-share, 5.09% holding in Recursion
Vanguard Capital Management LLC and its affiliates have disclosed a beneficial ownership of 26,744,129 shares, representing a 5.09% stake, in Recursion Pharmaceuticals Inc. (RXRX) as of June 30, 2026. This Schedule 13G filing indicates Vanguard has sole voting power over 3,978,189 shares and sole dispositive power over all 26,744,129 shares. The disclosure clarifies that no other single person has an interest exceeding 5% through Vanguard's holdings.
RXRX (NASDAQ: RXRX) insider plans 75,000-share Class A stock sale
An insider at Recursion Pharmaceuticals, Inc. (RXRX) has filed a Rule 144 notice to sell 75,000 Class A shares through Fidelity Brokerage Services LLC, valued at approximately $225,000. These shares were acquired as Founder Shares for compensation on April 20, 2021. The filing also details numerous previous Class A share sales by Christopher C. Gibson and affiliated entities from May to July 2026.
BlackRock (RXRX holder) discloses 8.5% ownership in Recursion Pharmaceuticals Class A shares
BlackRock, Inc. has filed an amended Schedule 13G disclosing an 8.5% passive ownership stake in Recursion Pharmaceuticals, Inc.'s Class A shares. This amounts to 44,541,605 shares, with BlackRock holding sole voting power over 43,812,201 shares and sole dispositive power over all 44,541,605 shares. The filing indicates that no single underlying client or investor holds more than five percent of the outstanding common shares.
RXRX (RXRX) holder files to sell 50,000 Class A shares after prior sales
A shareholder of Recursion Pharmaceuticals, Inc. (RXRX), associated with Christopher C. Gibson, has filed a Form 144 to sell 50,000 Class A shares valued at over $151,000. These shares are identified as Founders Shares initially acquired as compensation in April 2021. The filing also details numerous previous sales of Class A shares by Gibson and related entities over the past three months.
Recursion Pharmaceuticals, Inc. Class A Revenue Breakdown – BMV:RXRX
Recursion Pharmaceuticals, Inc. (BMV:RXRX) generated 1.34 billion Mexican Pesos in revenue last year. The majority of this revenue, 1.35 billion MXN, came from its Drug Discovery segment. The United States was the largest geographical contributor, accounting for 709.28 million MXN of the company's revenue.
Recursion Pharmaceuticals, Inc. Class A Revenue Breakdown – SWB:8RL
This article provides a revenue breakdown for Recursion Pharmaceuticals, Inc. Class A (SWB:8RL), highlighting its top-performing segment and geographical contribution. Last year, the company generated 63.22 million EUR, with the Drug Discovery segment contributing 63.58 million EUR, and the United States accounting for 33.50 million EUR of the revenue.
Recursion Pharmaceuticals, Inc. Class A Revenue Breakdown – BIVA:RXRX
This article provides a revenue breakdown for Recursion Pharmaceuticals, Inc. Class A (BIVA:RXRX). The company generated 1.34 billion MXN last year, with its Drug Discovery segment contributing the most at 1.35 billion MXN. The United States was the largest regional contributor, accounting for 709.28 million MXN.
RXRX (RXRX) insider details 50,000-share planned sale and recent stock trades
Christopher C. Gibson, an insider at RXRX, plans to sell 50,000 Class A shares of Recursion Pharmaceuticals (RXRX) via Fidelity Brokerage Services LLC on NASDAQ, valued at approximately $152,702.73. These shares were originally acquired as founder's compensation in 2021. The filing also details numerous prior Class A share sales by Gibson and related entities, including the Gibson Family Trust and Lahwran-3 LLC, over the past three months, with significant aggregate proceeds.
RXRX insider to sell 100,000 Class A shares (NASDAQ: RXRX) after prior large trades
An insider at Recursion Pharmaceuticals (RXRX) has filed a Form 144 notice to sell 100,000 Class A shares with an aggregate market value of over $304,000. These shares are identified as Founders Shares issued as compensation in 2021. The filing also reveals numerous large Class A share sales by Christopher C. Gibson and related entities over the past three months, some in excess of 340,000 shares.
RXRX (RXRX) insider files Form 144 to sell 100,000 Class A shares
An insider associated with Recursion Pharmaceuticals, Inc. (RXRX) has filed a Form 144 to sell 100,000 Class A shares, valued at $289,766.37, through Fidelity Brokerage Services on July 20, 2026. These are documented as founder shares acquired as compensation on April 20, 2021. The filing also notes several previous Class A share sales by Christopher C. Gibson, Gibson Family Trust, and Lahwran-3 LLC over the past three months.
Recursion Pharmaceuticals (RXRX) Highlights Clinical Progress, Is The Stock Fully Priced?
Recursion Pharmaceuticals (RXRX) has highlighted positive clinical progress for REC-1245 and REC-4881, alongside FDA discussions and interest from ARK Investment. Despite these updates, the stock's recent momentum has cooled, raising questions about whether current valuations reflect these catalysts or if further upside exists. While one narrative suggests the stock is overvalued with a fair value of $1.97, another discounted cash flow model by Simply Wall St indicates it is undervalued at $10.13 per share.
Recursion Pharmaceuticals director Borgeson sells $158,500 stock By Investing.com
Recursion Pharmaceuticals director Blake Borgeson sold 40,000 shares of Class A Common Stock for a total of $158,500, pursuant to a Rule 10b5-1 trading plan. The sale occurred on July 7, 2026, with shares sold between $3.95 and $4.00. This transaction leaves Borgeson with 6,218,287 shares, and the company recently reported mixed Q1 2026 earnings and elected new Class II directors.
Recursion Pharmaceuticals (RXRX) director sells 40,000 shares in 10b5-1 trade
Recursion Pharmaceuticals (RXRX) director Blake Borgeson sold 40,000 shares of Class A common stock on July 7, 2026, at a weighted average price of $3.9625 per share, totaling approximately $159,000. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025. Following the transaction, Borgeson directly holds 6,218,287 shares of the company.
RXRX: Founder’s 40,000 Class A shares listed; insider sales reported (RXRX)
A Form 144 filing for Recursion Pharmaceuticals (RXRX) indicates that 40,000 Class A founder's shares are listed for sale. The filing also discloses three recent dispositions of 30,000 Class A shares each by Blake C. Borgeson on April 7, May 5, and June 2, 2026, with their respective gross proceeds reported. The filing was accepted by the SEC EDGAR on July 7, 2026, at 11:37 AM.
Recursion Pharmaceuticals (RXRX) director granted 5,109 Class A shares
Recursion Pharmaceuticals (RXRX) director Zavain Dar was granted 5,109 Class A shares at no cash cost under the company’s Outside Director Compensation Policy. Following this award, Dar directly holds 240,764 Class A shares. This transaction was reported in a Form 4 filing and categorized as an acquisition reflecting standard director compensation.
Recursion (NASDAQ: RXRX) director Dean Y. Li receives 3,747-share equity grant
Recursion (NASDAQ: RXRX) director Dean Y. Li has received an equity grant of 3,747 Class A shares as compensation under the company’s Outside Director Compensation Policy. This grant increases his direct holdings to 1,473,329 Class A shares. Additionally, Li indirectly holds 421,000 Class A shares through the Dean Y. Li 2021 Family Trust and 1,422,048 Class A shares through the Dean Y. Li Revocable Trust.
Christopher C. Gibson lists multiple Class A sales (RXRX)
Christopher C. Gibson, an insider at Recursion Pharmaceuticals, Inc. (RXRX), has filed a Form 144 notice for proposed sales of Class A common stock. The filing details several disposition dates and share quantities, including a significant 100,000 share entry dated July 1, 2026, and a 340,440 share entry from June 18, 2026. These are proposed transactions rather than completed sales.
RXRX (NASDAQ: RXRX) insider sale notice — 100,000 Class A shares
Recursion Pharmaceuticals (NASDAQ: RXRX) has filed a Form 144 disclosing a prospective sale of 100,000 Class A shares resulting from restricted stock vesting on May 15, 2025. The filing also notes previous dispositions by Christopher C. Gibson, including 340,440 shares sold for over $1 million between April and June 2026. This notice is an administrative intent to sell and does not confirm actual sale completion.
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
GT Biopharma, Inc. (NASDAQ: GTBP) is leveraging AI-based tools to accelerate its drug discovery and engineering efforts, expecting multiple new development candidates to enter pre-IND development in 2027. This strategy aims to improve efficiency, reduce costs, and shorten timelines in designing tumor-targeting drugs, expanding potential indications beyond oncology. The update comes as the company advances two TriKE candidates, GTB-3650 and GTB-5550, through Phase 1 clinical trials, highlighting a dual focus on current clinical execution and building a faster, cheaper pipeline for the future.
Recursion Pharmaceuticals, Inc. Class A Actuals & Estimates (NASDAQ:RXRX)
This article provides an overview of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers frequently asked questions regarding the stock's ticker, price volatility, earnings reports, revenue, net income, and dividend policy. The article also provides guidance on how to buy RXRX stocks through online brokers and advises on due diligence before investing.
8RL Forecast — Price Target — Prediction for 2027
This article provides a forecast for Recursion Pharmaceuticals, Inc. Class A (8RL) stock, including a price target of 5.69 EUR based on analyst estimates. It outlines key financial metrics such as recent earnings and revenue, and provides information on employee count and EBITDA. The report also addresses frequently asked questions about the stock, including how to buy shares and upcoming earnings dates.
RXRX Forecast — Price Target — Prediction for 2027
This article provides a forecast for Recursion Pharmaceuticals, Inc. (RXRX) stock, including analyst price targets and ratings. It details the company's financial performance, such as recent earnings and revenue, and answers common questions about its stock performance, market capitalization, and upcoming earnings dates.
Recursion (NASDAQ: RXRX) director receives 88,424-share restricted stock grant
Recursion Pharmaceuticals (NASDAQ: RXRX) director Robert Hershberg was granted 88,424 restricted stock units (RSUs) as a routine award under the company’s Outside Director Compensation Policy. These RSUs vest on the earlier of June 17, 2027, or the day before the company’s 2027 annual stockholder meeting, contingent on his continued service. Following this grant, Hershberg directly holds 162,156 shares of Class A Common Stock.
Recursion (NASDAQ: RXRX) director gets 88,424 RSUs, sells 3,963 shares
Recursion Pharmaceuticals, Inc. director Namandje Bumpus received a grant of 88,424 restricted stock units (RSUs) on June 17, 2026, which vest on the earlier of June 17, 2027, or the day before the 2027 annual stockholders’ meeting. Concurrently, on June 18, 2026, Bumpus sold 3,963 shares of Class A Common Stock at $3.18 per share through a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Bumpus directly owns 127,632 shares of Class A Common Stock.
Recursion (NASDAQ: RXRX) director Elaine Sun receives 88,424 restricted stock units
Recursion Pharmaceuticals (NASDAQ: RXRX) director Elaine Sun has been granted 88,424 restricted stock units (RSUs) as an equity award, with no cash cost, under the company’s Outside Director Compensation Policy. These RSUs will vest on the earlier of June 17, 2027, or the day before the 2027 Annual Meeting of Stockholders, contingent on her continued service. Following this transaction, Sun directly holds 135,981 shares of Class A Common Stock.
Recursion (NASDAQ: RXRX) director Dean Y. Li granted 88,424 RSUs, updates holdings
Recursion (NASDAQ: RXRX) director Dean Y. Li was granted 88,424 restricted stock units (RSUs) as part of the company's Outside Director Compensation Policy. These RSUs, valued at $0.00 per share, are set to vest on June 17, 2027, or the day before the 2027 Annual Meeting of Stockholders, provided Mr. Li continues his service. Following this grant, Dean Y. Li's direct holdings in Class A Common Stock now total 1,469,582 shares, in addition to substantial indirect holdings through family trusts.
Recursion (RXRX) director receives 88,424 restricted stock units award
Recursion Pharmaceuticals (RXRX) director Blake Borgeson was granted 88,424 restricted stock units of Class A common stock under the company’s Outside Director Compensation Policy. These units will vest on the earlier of June 17, 2027, or the day before the 2027 annual stockholder meeting, contingent on his continued service. This award increases his direct holdings to 6,258,287 shares.
Recursion (NASDAQ: RXRX) director gets 88,424 restricted stock units
Recursion Pharmaceuticals (NASDAQ: RXRX) director Franziska Michor was granted 88,424 restricted stock units as compensation under the company's Outside Director Compensation Policy. These units were granted at $0.00 per share and will vest on June 17, 2027, or the day before the company's 2027 Annual Meeting of Stockholders, contingent on her continued board service. Following this grant, Michor directly holds 215,477 shares of the company’s Class A Common Stock.
Recursion (RXRX) director Zavain Dar granted 88,424 restricted stock units
Recursion Pharmaceuticals (RXRX) director Zavain Dar was granted 88,424 restricted stock units (RSUs) for board service. These RSUs, valued at $0.00 per share, will vest on the earlier of June 17, 2027, or the day before the 2027 annual stockholder meeting, contingent on continued service. Following this transaction, Dar's direct holdings in Recursion Pharmaceuticals Class A Common Stock amount to 235,655 shares.
Recursion Pharmaceuticals (RXRX) Proxy filing Summary
Recursion Pharmaceuticals (RXRX) will hold its annual meeting virtually on June 17, 2026, where shareholders will vote on the election of two Class II directors, executive compensation, and auditor ratification. The company, a clinical-stage TechBio firm, uses AI for drug discovery and development. The board recommends approval of all proposals, emphasizing shareholder participation.
Recursion (NASDAQ: RXRX) investors back board nominees and PwC as 2026 auditor
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) shareholders approved all management proposals at their 2026 annual meeting on June 17, 2026. Shareholders re-elected Class II directors Najat Khan, Ph.D., and Franziska Michor, Ph.D., and advisory approved executive compensation. They also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, demonstrating continued support for the company's governance and compensation practices.
RXRX (NASDAQ) proposed resale of multiple 40,000-share blocks between Mar–Jun 2026
RXRX (Recursion Pharmaceuticals, INC.) has filed a Form 144, indicating proposed resales of Class A founder shares. The filing details multiple 40,000-share blocks with potential trade dates spanning from March to June 2026, each with an associated dollar value. Fidelity Brokerage Services LLC is listed as the broker for these transactions, which are described as compensation-originated or founder-held shares.
Christopher C. Gibson sells six 40,000-share lots (RXRX) across Mar–Jun 2026
Christopher C. Gibson, an insider at Recursion Pharmaceuticals (RXRX), filed a Form 144 detailing six separate sales of 40,000 Class A shares each between March and June 2026. The filing also indicates scheduled restricted stock vesting events for Class A shares in 2025 and 2026. Analysts describe these transactions as routine dispositions, with explicit share counts and gross proceeds noted for each sale.
RXRX (NASDAQ) affiliate files Form 144 to sell 3,963 Class A shares
An affiliate of Recursion Pharmaceuticals (RXRX) has filed a Form 144, indicating an intent to sell 3,963 Class A shares resulting from restricted stock vesting on June 18, 2026. This filing also discloses a prior sale of 4,386 Class A shares by Namandje Bumpus on June 3, 2026. The filing is a routine disclosure related to compensation and vests shares, rather than a strategic sale.
Recursion (NASDAQ: RXRX) CFO covers taxes with 5,396 withheld shares
Recursion Pharmaceuticals' CFO, Ben R. Taylor, reported a tax-related disposition where 5,396 shares of Class A Common Stock were withheld to cover tax obligations stemming from restricted stock units. The shares were withheld at a price of $3.15 per share. Following this transaction, Taylor directly holds 1,101,876 shares of Class A Common Stock.
Recursion Pharmaceuticals (RXRX) Stock Could Be 67% Overvalued After Pipeline Updates
Recursion Pharmaceuticals (RXRX) is gaining attention due to recent clinical updates and an upcoming presentation at the Goldman Sachs Global Healthcare Conference, leading to a recent share price increase. Despite this, some analyses suggest the stock is significantly overvalued, with a fair value estimate of $1.97 compared to the current $3.29, driven by an aggressive growth narrative. However, a discounted cash flow model suggests a higher value of $9.09, indicating conflicting views on the stock's true potential amidst ongoing net losses and past underperformance.
Early Safety Data And FDA Signals Might Change The Case For Investing In Recursion Pharmaceuticals (RXRX)
Recursion Pharmaceuticals' investment case is being reshaped by early safety data for REC-1245 in solid tumors and anticipated FDA feedback on REC-4881, which are key catalysts for its AI-driven drug discovery platform. While the initial safety profile of REC-1245 is positive, investor focus remains on translating AI tools into clinical and regulatory outcomes amidst ongoing cash burn. The article suggests that Recursion's forecasts yield a significant upside to its current price, but also highlights the need to consider risks and other perspectives.
Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock
Recursion Pharmaceuticals CEO Najat Khan sold 23,588 shares of RXRX stock totaling $84,459 on June 5, 2026, through a pre-planned trading arrangement. Despite this sale, Khan still holds over 2.1 million shares, and the company is considered undervalued by InvestingPro. The company recently reported mixed Q1 2026 earnings, exceeding EPS expectations but missing revenue forecasts, while AI is projected to significantly reduce drug development costs across the industry.
Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After Positive AI Drug Data And Extended Cash Runway
Recursion Pharmaceuticals (RXRX) saw its stock rise by 9.5% following positive early clinical data from its AI-driven drug discovery programs and a reduced cash burn, extending its capital runway into early 2028. This progress suggests its integrated TechBio model is yielding tangible results, strengthening its investment narrative. While the company's Q1 2026 update showed better-than-expected earnings and a narrower net loss, investors are cautioned that the early-stage pipeline still requires substantial future funding.
Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock By Investing.com
Najat Khan, CEO of Recursion Pharmaceuticals, sold 23,588 shares of RXRX stock for $84,459 on June 5, 2026, as part of a Rule 10b5-1 trading plan. Following the sale, Khan directly holds over 2.17 million shares, and the company has a market cap of $1.77 billion. The article also mentions recent Q1 2026 earnings, which beat EPS estimates but missed revenue targets, and the potential impact of AI on reducing drug development costs.
Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock
Recursion Pharmaceuticals CEO Najat Khan sold 23,588 shares of Class A Common Stock for $84,459 on June 5, 2026, as part of a pre-arranged trading plan. Following the sale, Ms. Khan retains over 2.1 million shares. The company recently reported mixed first-quarter 2026 earnings, with higher-than-expected EPS but a significant revenue shortfall, while the broader industry recognizes AI's potential for cost reduction in drug development.
